Skip to main content

Table 3 univariate analysis of prognostic factors for bPFS and cPFS

From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer

Patient characteristics

n

Median bPFS (months)

p-value

Median cPFS (months)

p-value

Age at diagnosis of oligometastases

  

0.007

 

0.008

 ≤ 70 years

33

34.3

 

Not reached

 

 > 70 years

47

13.4

 

15.0

 

Gleason score

  

0.622

 

0.877

 ≤ 8

40

18.3

 

21.6

 

 ≥ 9

40

15.9

 

18.5

 

Initial tumor stage

  

0.710

 

0.601

 ≤ T2

24

18.3

 

21.6

 

 ≥ T3

54

16.5

 

21.5

 

Initial nodal stage

  

0.658

 

0.227

 N0

51

15.9

 

17.5

 

 N1

21

21.2

 

80.1

 

PSA-DT

  

0.928

 

0.952

 ≤ 4 months

24

15.9

 

19.0

 

 > 4 months

25

13.6

 

15.2

 

Number of metastases

  

0.471

 

0.413

 1

53

16.1

 

18.5

 

 ≥ 2

27

16.5

 

34.8

 

Hormone-sensitivity

  

0.052

 

0.040

 HSPC

62

21.2

 

26.5

 

 CRPC

18

12.0

 

12.8

 

Category of oligometastatic disease

  

0.003

 

0.003

 De-novo synchronous oligometastatic disease

25

34.3

 

80.9

 

 De-novo metachronous oligorecurrent disease

37

16.1

 

19.0

 

 Other (de-novo oligoprogressive, repeat oligometastatic or induced oligometastatic disease)

18

10.3

 

12.4

 

Concomitant ADT

  

0.000007

 

0.000149

 Present

55

26.0

 

34.8

 

 Absent

25

9.2

 

12.4

 

Dose BED3

  

0.142

 

0.102

 ≤ 93 Gy

31

26.0

 

17.3

 

 > 93 Gy

49

13.9

 

80.9

 
  1. ADT, androgen deprivation therapy; BED, biologically effective dose; bPFS, biochemical progression-free survival; cPFS, clinical progression-free survival; CRPC, castration-resistant prostate cancer; HSPC, hormone-sensitive prostate cancer; PSA, prostate specific antigen; PSA-DT, PSA-doubling time